Cognition Therapeutics shares rise 1.49% premarket after Eisai and Biogen's LEQEMBI® approval in Australia.

Cognition Therapeutics, Inc. rose 1.49% in premarket trading. Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody 'LEQEMBI®' (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers.